Kornimate/medical-research-clean huggingface dataset:
personalized feedback intervention to reduce risky cannabis use.

Conditions: Cannabis Use

Summary: the purpose of this project is to determine whether participants who receive a personalized feedback report and educational materials about risky cannabis use will be less likely to report risky cannabis use at follow-up compared to participants who only received educational materials.

this project aims to reduce risky cannabis use among those with less severe cannabis use, most of whom will never seek formal treatment. all of the participants will receive educational material regarding risky cannabis use and its prevention. half of the participants will also be assigned by chance to receive a personalized feedback report. the investigators hypothesize that: 1. participants who receive the full personalized feedback intervention will be less likely to report risky cannabis use at 3- and 6-month follow-ups compared to participants who receive educational materials only (primary hypothesis). 2. participants who receive the full personalized feedback intervention will report greater reductions in their perceptions of how much others use cannabis at a 3-month follow-up compared to participants who receive educational materials only. 3. reductions in perceptions of how much others use cannabis at 3-month follow-up will be positively associated with reduction in the participant's risky cannabis use at 6-month follow-up. a 2-arm parallel group randomized controlled trial will be conducted to test these hypotheses with follow-ups occurring at 3 and 6 months after randomization. online media advertisements will be used to recruit people currently using cannabis. the advertisements will be placed across canada using locations found successful in previous trials to rapidly recruit participants (e.g. google adwords).

Eligibility criteria:
inclusion criteria: * score of 4 or more on the alcohol, smoking, and substance involvement screening test, cannabis subscale (assist) exclusion criteria: * being under 18 years of age
analysis of circulating epithelial tumor cells in peripheral blood in patients with primary non-metastatic breast cancer under adjuvant radiotherapy

Conditions: Breast Cancer Female

Summary: the aim of this study was to investigate the systemic effect of radiotherapy on patients with primary non-metastatic breast cancer using cetc and to analyze possible changes in cetc quantity under adjuvant radiotherapy.

in cooperation with the women's hospital of the friedrich schiller university in jena, a total of 161 patients with clinically proven, primarily non-metastatic breast cancer were sampled and examined before and after radiotherapy over a period from 09/2002 to 09/2012. the maintrac method was used to quantitatively determine the amount of cetc in the blood and to observe its peritherapeutic course.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast carcinoma * age \>= 18 years * exclusive treatment at the jena university hospital * complete curative-intended adjuvant or definite radiotherapy * at least 2 blood collections (before the start of therapy, after the end of the rt) exclusion criteria: * presence of metastases * recurrence * dcis, inflammatory breast cancer * second malignancy \<10 years before diagnosis of breast cancer * radiotherapeutic pretreatment

Keywords: radiotherapy cetc ctc breast cancer
efficacy and safety of gefapixant (mk-7264) in adult participants with recent onset chronic cough (mk-7264-043)

Conditions: Chronic Cough

Summary: the purpose of this study is to evaluate the efficacy and safety of gefapixant in participants with recent onset chronic cough (duration \>8 weeks after onset of cough symptoms) for \<12 months and a diagnosis of refractory or unexplained chronic cough. the primary hypothesis is that gefapixant is superior to placebo in improving cough-related quality of life measured as change from baseline in the leicester cough questionnaire (lcq) total score at week 12.


Eligibility criteria:
inclusion criteria: * chest radiograph or ct thorax (within 1 year of screening/visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease, in the opinion of the principal investigator or the subinvestigator * has chronic cough (defined as duration of \>8 weeks after onset of cough symptoms) for \<12 months prior to the screening visit (\<14 months after onset of cough symptoms) * has a diagnosis of refractory chronic cough or unexplained chronic cough * female participants are not pregnant, not breastfeeding, not of childbearing potential, or agree to follow contraceptive guidance exclusion criteria: * is a current smoker * has given up smoking within 12 months of screening * is a former smoker with a smoking history greater than 20 pack-years (1 pack of 20 cigarettes per day for 20 years) * has a history of respiratory tract infection or recent change in pulmonary status within 4 weeks of screening * has a history of chronic bronchitis, defined as cough that produces \>1 tablespoon of phlegm, that occurs every day for at least 3 months in a row * has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or cervical cancer * is a user of recreational or illicit drugs or a recent history (within the last year) of drug or alcohol abuse * has a history of anaphylaxis or cutaneous adverse drug reaction to sulfonamide-containing drugs * has a known allergy to gefapixant or its excipients * has donated or lost ≥1 unit (\~300 ml) of blood within 8 weeks prior to first dose of gefapixant * has previously received gefapixant * is currently participating or has participated in an interventional clinical study within 30 days of participating in this current study

Keywords: cough respiration disorders respiratory tract diseases signs and symptoms, respiratory signs and symptoms
investigation of the clinical efficacy of low-dose ionizing radiation in the treatment of osteoarthritis

Conditions: Arthrosis; Osteoarthritis

Summary: immo-ldrt02 is a prospective, placebo-controlled, double-blind, randomized trial to investigate the clinical efficacy of low dose radiation therapy (ldrt) in the treatment of arthrosis. newly diagnosed or already existing arthroses of the fingers, wrists, shoulders, knees, ankles and feet will be enclosed. finally, the evidence of clinical benefit from ldrt (6 x 0.5 gy) will be compared to the placebo group (6 x 0 gy), by determination via a visual analog scale and identification of immunological changes.

the prevalence of chronic degenerative and inflammatory disorders, such as osteoarthritis, is constantly rising. as not all patients do respond adequately to the standard therapies, alternative treatment options such as low dose radiation therapy (ldrt) has gained further importance. ldrt is known to induce a long-lasting pain reduction, while having few side effects. nonetheless, the detailed biological and immunological modes of action remain mostly elusive. in addition, there is a lack in placebo controlled randomised controlled trials (rcts) proofing the pain-relieving effects of ldrt. so, the prospective, placebo-controlled, double-blind, randomized immo-ldrt02 trial to investigate the clinical efficacy of ldrt in the treatment of arthrosis should close this gap. newly diagnosed or already existing arthroses of the fingers, wrists, shoulders, knees, ankles and feet will be enclosed. finally, the evidence of clinical benefit from ldrt (6 x 0.5 gy) will be compared to the placebo group (6 x 0 gy), by determination via a visual analog scale (vas) and identification of immunological changes, which contribute to the success of therapy and are specifically found in the test group (immo-ldrt01 trial; clinicaltrials.gov identifier: nct02653079).

Eligibility criteria:
inclusion criteria: * diagnosed osteoarthritis according to acr criteria (exclusion of other other arthritides and chronic rheumatoid arthritis via laboratory tests): * finger and wrist osteoarthritis * elbow arthrosis * shoulder arthrosis * knee arthrosis * ankle and foot joint arthrosis * first time application of low-dose radiotherapy (ldrt) of the affected joint. * willingness to cooperate and accessibility of the patients (geographical proximity) for treatment and follow-up care exclusion criteria: * patients with tumor diseases * people capable of childbearing or procreation who do not take consistent contraceptive measures during therapy * persistent drug, medication or alcohol abuse * patients for whom, in the physician's judgment, participation is not justifiable with regard to their well-being due to temporary withdrawal of standard medication. * patients in whom the diagnosis of osteoarthritis of the affected joint cannot be made without doubt. to establish the diagnosis, the guidelines of the american college of rheumatology (acr) are followed. * earlier radiation therapy for treatment of cancer

Keywords: low dose radiotherapy ldrt
epi-gerd study: epidemiological evaluation in patients with gastro-esophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux Disease

Summary: cross-sectional epidemiological study in patients with diagnosis of gerd (gastroesophageal reflux disease) and with current treatment or with a history of recent treatment with some ppi (proton pump inhibitor), in order to evaluate the persistence and / or relapse of symptoms of gerd.

objective: to carry out an evaluation about the persistence and / or relapse of symptoms in colombian patients with diagnosis of gerd. materials and methods: a multicentric cross-sectional epidemiological study will be carried out in colombian patients with diagnosis of gerd and with current treatment or with a history of recent treatment with some ppi (proton pump inhibitor). the persistence and / or relapse of symptoms will be evaluated as the main variable. the secondary variables to be evaluated include: demographical analysis, treatment (s) used by patients, adverse events associated with the treatments, comorbidities and risk factors. the analysis will be carried out from two perspectives: a first descriptive approach and a second analytical approach, with a level of significance of 5%.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * previous diagnosis of gastroesophageal reflux disease (gerd) * current treatment with a proton-pump inhibitor (ppi), or not current treatment with some ppi but yes in the last year exclusion criteria: * refusal to participate in the study by the patient. * patients who, in the judgment of the investigator, do not understand or are not willing to adequately answer to the questions. * mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.
physiopathologic aspects and quality of life in participants with eye dark circles

Conditions: Periorbital Hyperpigmentation

Summary: this study will evaluate the physiopathologic characteristics of dark circles in participants with various ethnicities and fitzpatrick skin types and the impact of the dark circles on the quality of life.


Eligibility criteria:
inclusion criteria: * participants with fitzpatrick skin type i-vi * willingness to not wear any eye makeup on the day of the study visit prior to the study visit appointment * willingness to cleanse the face and remove all makeup at least 15 minutes prior to each scheduled clinic visit * willingness to have facial exams, skin instrumentation measurements, and digital photos performed on the face. exclusion criteria: * individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test area * uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune * individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.) * individuals who have had a blepharoplasty procedure or any other surgery in proximity or affecting the test area * individuals with recent procedures/surgeries (less than 6 months) on the eye bulb * individuals with permanent makeup around the eye area * chemical peel, microdermabrasion, microneedling, or dermaplaning in the previous 4 weeks * latisse, revitalash, or other lash enhancement stimulators in the previous 1 month * retin-a®, retin-a micro®, renova®, avita®, tazorac®, avage® or differin® or other similar prescription drugs within the previous 3 months * cosmetic injections (filler and/or toxins, i.e.juvederm, radiesse, botox, etc.), non- ablative laser or fractional laser resurfacing in the previous 12 months * accutane® or other oral retinoid, ablative procedures (i.e. laser, chemical) in the previous 12 months * individuals who have any planned surgeries or procedures during the study.
impact of hpv vaccination on prevention of cervical hpv infection in sikkim, india

Conditions: Cervical Cancer

Summary: this project aims is to monitor the effectiveness of hpv vaccination in real-word conditions, at least 7 years after initiation of hpv vaccination in sikkim. this study would give an opportunity to provide rapid feedback to the indian public health authorities about the impact of the hpv vaccine.

the investigators would like to estimate the prevalence of hpv infections based on cervical samples collected from the sikkimese women aged 18 to 22 years at baseline (i.e. when the study participants are expected to have no benefit of vaccination) and seven years after the launch of the hpv vaccination programme, by which time the initial vaccinated cohorts will be aged 18 to 22 years and many of them will be sexually active. if the vaccination programme continues with the current high coverage rate, the cohort of women in the second age group are expected to be protected due to herd immunity, irrespective of whether any individual woman receives the vaccine or not. overall effectiveness to protect women aged 18-22 years against targeted and non-targeted hpv infections will be monitored through repeated cervical sample -based surveys.

Eligibility criteria:
inclusion criteria: * women aged 18 to 22 years, resident of sikkim and married. * pregnancy will not be considered as exclusion criteria. * sample collection should be avoided during active menstruation. exclusion criteria: * women who do not provide written consent * women who are not able to cooperate in collection of cervical cell sample or respond to questions due to any acute or severe mental and physical illnesses. * women who had undergone hysterectomy. * vaccinated in research project
post-discharge monitoring initiative on outcomes of post-surgical patients

Conditions: Laparoscopy; Discharge Planning

Summary: the investigators are conducting a prospective study to evaluate the skh@home programme, a post-discharge monitoring initiative for surgical patients. the aim of this study is to conduct a pragmatic, non-randomized pilot study to compare the skh@home programme with standard post-surgical care on patient outcomes.


Eligibility criteria:
inclusion criteria: 1. patient is keen for home management 2. hemodynamically stable 3. able and willing to self-care and monitor / good social support 4. lives in singapore's northeast region either 5. diagnosed with intra-abdominal abscess requiring ongoing iv antibiotics as recommended by infectious diseases specialist where necessary or diagnosed with liver abscess requiring ongoing iv antibiotics as recommended by infectious diseases specialist where necessary and has undergone initial treatment (e.g., drainage if required) and is clinically improving or 6. underwent an uneventful straightforward bariatric surgical procedure, and has been monitored overnight without any immediate postoperative issues or underwent uneventful straightforward laparoscopic/ endoscopic/ minimally invasive surgery, and has been monitored for at least 6 hours without any immediate postoperative issues and has no significant intraprocedural concerns by the operating surgeon exclusion criteria: 1. unable to self-care / no caregiver 2. requires daily review by the surgical team 3. suspicion of surgical complications requiring surgical intervention 4. requires post-discharge monitoring care for \> 2 weeks 5. unregulated psychiatric disorders 6. daily flushing of drains required

Keywords: bariatric surgery laparoscopic surgery abdominal abscesses liver abscesses discharge planning
hybrid versus norwood management strategies in infants undergoing single ventricle palliation

Conditions: Congenital Heart Disease

Summary: the purpose of this trial is to determine, at 3 years of life, how the neurologic and functional outcomes in infants with single ventricles are different when comparing children treated with the hybrid strategy to the norwood strategy.

neurologic deficits in children with single ventricle physiology are believed to be associated with the reconstruction of the aortic arch during the initial norwood procedure as a neonate. in the last few years, a new management strategy (the 'hybrid' strategy) has been proposed which defers the aortic arch reconstruction to a second stage procedure at 4-6 months of age. proponents of the hybrid strategy assert that the avoidance of cardiopulmonary bypass and circulatory arrest in the neonatal period will avoid neurologic injury in the critical neonatal period and thereby result in superior long-term neurologic outcomes. we are testing whether the hybrid management strategy is associated with superior neurologic outcomes or not.

Eligibility criteria:
inclusion criteria: 1. diagnosis of functional single ventricle anatomy amenable to norwood or hybrid first stage palliation. 2. informed consent of parent(s) or legal guardian. exclusion criteria: 1. pre-operative identification of anatomy rendering either a norwood or hybrid procedure clinically inappropriate; 2. recent history of significant cerebral bleed or necrotizing enterocolitis; 3. severe hemodynamic instability; 4. any other major congenital abnormality (i.e. congenital diaphragmatic hernia, tracheoesophageal fistula) or clinically significant acquired extra-cardiac disorder (e.g. meconium aspiration with need for high frequency ventilation, persistent renal failure requiring dialysis).

Keywords: hybrid norwood congenital heart disease single ventricle
prospective relationship between the rates of spontaneous passage of distal ureteral stones and the distal lumen

Conditions: Ureter Stone

Summary: patients (female, male, or queer) with ureteral stones (smaller than 1 cm at the widest diameter of the stone) without pyonephrosis, urinary sepsis, or untraceable pain will be enrolled into the study. ureteral width at the smallest area of the ureter (in most cases uv junction) will be noted during regular ultrasound scans. the ratio of ureteral width to the stone diameter will be correlated with the spontaneous stone passage.


Eligibility criteria:
inclusion criteria: ureteral stone smaller than 1 cm volunteer to be enrolled exclusion criteria: pyonephrosis urinary sepsis untraceable pain
ultrasound study in pregnant women with malaria

Conditions: Pregnant Women; Malaria

Summary: most of the neonatal deaths that occur worldwide every year are associated with low birth weight (lbw), caused by intrauterine growth restriction (iugr) and/or preterm delivery. accurate assessment of fetal growth and gestational age for timely identification and management of growth restriction are therefore public health priorities, especially in developing countries where 98% of all neonatal deaths occur. every year, more than 50 million women become pregnant in malaria endemic regions. malaria infection at any time during pregnancy reduces birthweight. however, little is known about the relationship between the timing of infection during pregnancy and the extent of the impact on birth weight. the mechanisms by which malaria causes lbw also remain unclear. reduced placental blood flow, placental changes, red blood cell changes, severe anaemia and pro-inflammatory cytokines have all been implicated. in this proposed, longitudinal, observational, minimal risk study, which will take place in smru antenatal clinics on the thai-burmese border, the effect of malaria infection during pregnancy on fetal growth will be determined. women will be screened before 13+6 weeks of gestation and followed with regular ultrasound examinations during pregnancy. when a woman has a malaria infection an extra ultrasound scan will be done to measure growth retardation or placental blood flow changes. bloodsamples will be taken to detect changes in red blood cell properties and putative markers of malaria infection. for this study the maximum amount of blood taken during pregnancy is 13 cc in an uninfected woman. for each malaria episode an additional 7 cc blood will be taken. after delivery a placenta and a cord sample will be taken to detect placental changes. the investigators aim to recruit four hundred pregnant women over the course of two years. this study involves minimal risk to participants as ultrasound examination is part of routine antenatal care in many countries in the world.


Eligibility criteria:
inclusion criteria: * singleton viable pregnancy. if not detected at enrolment, multiple pregnancies will be excluded from the analysis. * age ≥18 years old. * willing and able to participate and comply with the study protocol and attend the smru ancs regularly. * ega between 9+0 and 13+6 weeks by ultrasound (crl) * able to communicate in burmese, karen or english language * written informed consent to participate in trial and follow consultation exclusion criteria: * evidence of major congenital abnormality in the present pregnancy (e.g. anencephaly, omphalocele, hydrocephalus). * known chronic maternal illness. * thai national whose primary language is thai

Keywords: malaria ultrasound pregnancy pregnant women (infected with malaria and without)
post marketing surveillance for contac bien z in japan

Conditions: Allergic Rhinitis; Seasonal Allergic Rhinitis

Summary: this is a post-marketing surveillance study on a marketed cetrizine hydrochloride formulation.


Eligibility criteria:
inclusion criteria: * male and female participants, between 15-65 years of age, who purchase the marketed cetrizine hydrochloride formulation exclusion criteria: * who have ever experienced allergic symptoms by taking this medication or any component of this medication, piperazine derivative (including levocetirizine, hydroxizine) * those who have been under 15en diagnosed with kidney disease * children under 15 years of age
effect of inflammation on pharmacokinetics of posaconazole

Conditions: Mycoses

Summary: posaconazole plasma concentration and inflammatory markers will be determined in all samples available from routine analysis.

a prospective observational study will be performed at the university medical center groningen, the netherlands using longitudinal data collection. the design of the study will be that patients starting on posaconazole treatment will be evaluated. after informed consent is obtained medical data will be collected from the medical chart. posaconazole plasma concentration (trough levels) and inflammatory markers (e.g. c-reactive protein) will be determined in all samples available from routine analysis (often daily). this will result in a detailed data set capturing day to day variations in inflammation and drug concentrations.

Eligibility criteria:
inclusion criteria: * \>18 yrs * receiving posaconazole * written informed consent exclusion criteria: * none